Louisiana State Employees Retirement System Invests $781,000 in LivaNova PLC (NASDAQ:LIVN)

Louisiana State Employees Retirement System purchased a new stake in LivaNova PLC (NASDAQ:LIVN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,100 shares of the company's stock, valued at approximately $781,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Headlands Technologies LLC purchased a new position in shares of LivaNova during the third quarter worth about $72,000. Picton Mahoney Asset Management purchased a new position in shares of LivaNova during the third quarter worth about $91,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of LivaNova during the third quarter worth about $217,000. AlphaMark Advisors LLC purchased a new position in shares of LivaNova during the third quarter worth about $244,000. Finally, Jump Financial LLC purchased a new position in shares of LivaNova during the third quarter worth about $273,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

LivaNova Price Performance

NASDAQ:LIVN traded up $0.43 during trading hours on Friday, reaching $55.53. 553,327 shares of the company traded hands, compared to its average volume of 554,401. The firm's 50-day moving average is $54.13 and its 200-day moving average is $50.64. The stock has a market cap of $3.00 billion, a P/E ratio of 173.54 and a beta of 0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.95 and a quick ratio of 2.51. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $59.86.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.77 by $0.10. The business had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The business's revenue for the quarter was up 12.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.81 earnings per share. Equities research analysts expect that LivaNova PLC will post 3.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LIVN. StockNews.com raised LivaNova from a "hold" rating to a "buy" rating in a report on Thursday. Robert W. Baird lifted their price objective on LivaNova from $56.00 to $62.00 and gave the company a "neutral" rating in a report on Thursday, February 22nd. Needham & Company LLC reiterated a "buy" rating and set a $72.00 price target on shares of LivaNova in a research report on Wednesday, March 20th. Barclays lifted their price target on shares of LivaNova from $57.00 to $61.00 and gave the company an "equal weight" rating in a research report on Monday, February 26th. Finally, Mizuho reiterated a "buy" rating and set a $75.00 price target on shares of LivaNova in a research report on Wednesday, March 27th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $64.40.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.